Q-omics provides the consensus-scored GARNL3 profile across patient tissues and cancer cell-line models. GARNL3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GARNL3 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, GARNL3 RNA expression shows 21,472 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, THCA, and LSCC as cancer lineages where GARNL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GARNL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GARNL3 survival associations across molecular data types. GARNL3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GARNL3 RNA expression–survival associations across cancer types. High GARNL3 expression shows unfavorable associations in UCEC, but favorable associations in BLCA, KIRC, HNSC, KIRP and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GARNL3 RNA expression.
This table summarizes GARNL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GARNL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GARNL3 shows lower tumor expression in THCA, BLCA, UCEC, BRCA and LUAD and higher tumor expression in KICH. The THCA box plot shows higher GARNL3 RNA expression in normal versus tumor tissue (log2 FC = −1.592, t-test p < 0.001).
This table shows molecular features associated with GARNL3 in patient tissues and cancer cell lines. In patient samples, GARNL3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GARNL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
